New results from the SELECT2 trial also show benefit of the procedure in a large range of ischemic core sizes and in patients transferred from an outside hospital.
A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health. Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors, natural sensors located in the wall of the carotid artery.